Evidence map›Paper›PMID 32042471›Full record

ArticleLiver research (Beijing, China)2019

Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist.

Adnan Malik, Ani A Kardashian, Kais Zakharia, Christopher L Bowlus, James H Tabibian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver research (Beijing, China), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Adnan MalikDepartment of Public Health and Business Administration, The University of Alabama at Birmingham, Birmingham, AL, USA.
Ani A KardashianUniversity of California Los Angeles Gastroenterology Fellowship Training Program, Vatche and Tamar Manoukian Division of Digestive Diseases, Los Angeles, CA, USA.
Kais ZakhariaDivision of Gastroenterology and Hepatology, University of Iowa, Iowa, IA, USA.
Christopher L BowlusDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, CA, USA.
James H TabibianDivision of Gastroenterology, Department of Medicine, Olive View-University of California Los Angeles Medical Center, Sylmar, CA, USA.
University of California, Los Angeles · USUniversity of Alabama at Birmingham · USUniversity of California, Davis · USUniversity of Iowa · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
NCATS NIH HHS UL1 TR000135
6 · The paper itself

Abstract

Cholestatic liver diseases (CLDs) encompass a variety of disorders of abnormal bile formation and/or flow. CLDs often lead to progressive hepatic insult and injury and following the development of cirrhosis and associated complications. Many such complications are clinically silent until they manifest with severe sequelae, including but not limited to life-altering symptoms, metabolic disturbances, cirrhosis, and hepatobiliary diseases as well as other malignancies. Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are the most common CLDs, and both relate to mutual as well as unique complications. This review provides an overview of PSC and PBC, with a focus on preventive measures aimed to reduce the incidence and severity of disease-related complications.

Indexed as

Biliary tract diseasesCirrhosisInflammatory bowel disease (IBD)Metabolic bone diseasePrimary biliary cholangitis (PBC)Primary sclerosing cholangitis (PSC)ProphylaxisPruritus

Identifiers

PMID32042471
PMCPMC7008979
OpenAlexW2947161907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.